We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

127 hedge funds and large institutions have $297M invested in Lyell Immunopharma in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

16% more capital invested

Capital invested by funds: $256M → $297M (+$40.5M)

8% more funds holding

Funds holding: 118 → 127 (+9)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0% less ownership

Funds ownership: 2.62% → 2.61% (-0%)

7% less call options, than puts

Call options by funds: $14K | Put options by funds: $15K

18% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 44

Holders
127
Holders Change
+9
Holders Change %
+7.63%
% of All Funds
1.83%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
23
Increased
36
Reduced
44
Closed
13
Calls
$14K
Puts
$15K
Net Calls
-$1K
Net Calls Change
-$1K

Top Buyers

1
OM
Opaleye Management
Massachusetts
+$7.18M
2
Millennium Management
Millennium Management
New York
+$2.44M
3
JP Morgan Chase
JP Morgan Chase
New York
+$1.05M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$800K
5
Renaissance Technologies
Renaissance Technologies
New York
+$751K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$5.76M
2
Bank of America
Bank of America
North Carolina
-$3.09M
3
Morgan Stanley
Morgan Stanley
New York
-$1.18M
4
HF
HRT Financial
New York
-$963K
5
BlackRock
BlackRock
New York
-$877K
Name Holding Trade Value Shares
Change 		Change in
Stake
Mirae Asset Global Investments
126
Mirae Asset Global Investments
South Korea
– -$437K -11,275 Closed
IC
127
IEQ Capital
California
– -$159K -4,108 Closed
PMEF
128
Point72 Middle East FZE
United Arab Emirates
– -$134K -3,443 Closed
Man Group
129
Man Group
United Kingdom
– -$105K -2,710 Closed
YIH
130
Y-Intercept (HK)
Hong Kong
– -$94.6K -2,439 Closed
BHCM
131
Brevan Howard Capital Management
Jersey
– -$50.6K -1,305 Closed
RL
132
RPO LLC
Connecticut
– -$38.3K -987 Closed
AIM
133
Aigen Investment Management
New York
– -$29.6K -763 Closed
VF
134
Virtu Financial
New York
– -$29K -759 Closed
PAS
135
Point72 Asia (Singapore)
Singapore
– -$25.2K -650 Closed
Qube Research & Technologies (QRT)
136
Qube Research & Technologies (QRT)
United Kingdom
– -$16.5K -425 Closed
BMC
137
Bear Mountain Capital
Washington
– -$12.9K -305 Closed
FFA
138
Farther Finance Advisors
California
– -$2 – –
Carson Wealth (CWM LLC)
139
Carson Wealth (CWM LLC)
Nebraska
– +$43 +1 +14%
2 3 4 5
6

LYEL Hedge Fund Activity: Q1 2024 in Review

127 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q1 2024, worth a combined $297M — up 16% from $256M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LYEL positions and 13 closed out — a net gain of 10 holders — while 36 added to existing stakes and 44 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $7.18M. The largest seller was Citadel Advisors, cutting an estimated $5.76M.

  • 127 institutional investors held Lyell Immunopharma (LYEL) as of Q1 2024, up from 118 in Q4 2023.
  • Funds reported $297M of Lyell Immunopharma stock for Q1 2024, up 16% quarter-over-quarter.
  • 23 funds opened new Lyell Immunopharma positions in Q1 2024 and 13 closed out, a net change of +10 holders.
  • The largest Lyell Immunopharma buyer in Q1 2024 was Opaleye Management, an estimated $7.18M added.
  • The largest Lyell Immunopharma seller in Q1 2024 was Citadel Advisors, an estimated $5.76M sold.

Based on aggregated 13F filings for Q1 2024.